Cormorant Asset Management, LP Ambrx Biopharma Inc. Transaction History

Cormorant Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.3 - $16.6 $2.86 Million - $5.11 Million	307,534 Added 3.2%	9,923,689 $114 Million
Q2 2023 Aug 14, 2023	BUY	$7.66 - $16.46 $8.55 Million - $18.4 Million	1,116,155 Added 13.13%	9,616,155 $158 Million
Q1 2023 May 15, 2023	BUY	$1.46 - $12.54 $9 Million - $77.3 Million	6,163,611 Added 263.81%	8,500,000 $75.8 Million
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.96 $158,996 - $443,991	-149,997 Reduced 6.03%	2,336,389 $2.52 Million
Q2 2021 Aug 16, 2021	BUY	$15.95 - $19.6 $39.7 Million - $48.7 Million	2,486,386 New	2,486,386 $47 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.